Post-effective amendment to a registration statement that is not immediately effective upon filing

Commitments and Contingencies (Details)

v3.22.1
Commitments and Contingencies (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Jan. 10, 2022
Jul. 27, 2021
Jul. 01, 2021
Mar. 28, 2021
Sep. 18, 2020
Dec. 31, 2021
Dec. 31, 2020
Oct. 09, 2020
Commitments and Contingencies [Line Items]                
Rent expense           $ 100 $ 100  
Allowance for doubtful accounts             257  
Accrued settlement expense             39,486  
Additional settlement liability       $ 21,400   $ 21,366 39,486  
Number of shares issued upon exercise of warrants   1,833,596       516,025    
Proceeds from issuance of common stock for exercise of warrant   $ 9,200       $ 16,699    
Prepaid expenses and other current assets           5,109 240  
GEM Warrant [Member]                
Commitments and Contingencies [Line Items]                
Warrant issued       3,329,812        
Exercise price of warrant       $ 3.19        
Warrants to purchase shares       1,496,216        
Warrants to purchase shares, amount       $ 7,500        
Warrants expire period       The GEM Warrant was valid for a period of three years from the date NeuroRx’s stock is listed for trading on a national securities exchange or consummation of a reverse merger transaction of the type contemplated by the Merger Agreement.        
Accrued settlement expense             $ 39,500  
Reimbursements from Relief Therapeutics Holding AG                
Commitments and Contingencies [Line Items]                
Payment to related party         $ 10,900 $ 10,900    
Phase II Inhaled clinical trial of Aviptadil                
Commitments and Contingencies [Line Items]                
Research commitments     $ 7,400          
GEM Share Subscription Facility Agreement                
Commitments and Contingencies [Line Items]                
Share subscription agreement term           3 years    
Share subscription value           $ 95,600    
Commitment fee           1,900    
Relief Therapeutics Collaboration Agreement Breach [Member]                
Commitments and Contingencies [Line Items]                
Further punitive damages $ 185,000              
Polypeptide [Member]                
Commitments and Contingencies [Line Items]                
Purchase commitments               $ 5,300
Prepaid expenses and other current assets           3,300    
Sponsored Research Agreement [Member]                
Commitments and Contingencies [Line Items]                
Research commitments           400    
Research commitments paid           $ 300